dasatinib + gemcitabine

Dasatinib + gemcitabine is an *investigational combination therapy* of two distinct small-molecule drugs for oncology indications. **Dasatinib** is a multi-kinase inhibitor, notably targeting BCR-ABL and SRC family kinases, with direct activity on tyrosine kinases implicated in tumor growth, survival, and metastasis. **Gemcitabine** is a nucleoside analog (antimetabolite) chemotherapeutic agent that inhibits DNA synthesis, leading to cell death. Preclinical evidence shows dasatinib may overcome gemcitabine resistance via inhibition of the Src pathway, prompting combination trials especially in *advanced solid tumors*, including pancreatic cancer, thymoma, anal cancer, and inflammatory breast cancer. Early phase clinical studies suggest tolerability and some preliminary activity in treatment-refractory tumors[1][2][4][3].